Business Wire

NC-SYNECHRON

1.4.2016 08:01:26 CEST | Business Wire | Press release

Share
Synechron to Integrate Double Effect and Team Trade to Bolster Its Consulting and Technology Capabilities

Synechron, one of the fastest growing digital, business consulting and technology service providers, announced its corporate brand integration with Double Effect and Team Trade - companies it had acquired in the past few years, to further augment its consulting and technology capabilities. Post-acquisition, Double Effect and Team Trade were operating as independent entities and brands. However, this brand integration strategy will see both these entities merging into the parent company – Synechron, fortifying the overall consulting and technology business/practice. As part of Synechron’s recently announced ‘Power of 3’ strategy, this move is also aimed at providing all consulting and technology services combined with digital under a single brand umbrella in order to leverage Synechron’s robust brand equity, also fueling its ambition of being a billion dollar company by 2020.

Founded in 2003 in Amsterdam, Double Effect houses 100+ business consultants spread across eight global locations. The Dutch consulting firm works for banking and financial institutions including corporate, investment and retail banks, asset management companies and pension as well as insurance services. In 2013, Double Effect became part of the Synechron group.

Team Trade, founded in 2000, is a Paris-based firm specializing in business consulting and financial software integration. The firm has significant presence in Paris, Luxembourg, Milan, London, New York and Singapore covering the European, North American and Asian markets. Team Trade became part of the Synechron group in December 2014.

“Double Effect’s business consulting portfolio is perfectly aligned with the geographical, business, client and service coverage of Synechron. By operating as a consulting arm of the Synechron brand, all our client relationships and alliances will witness a greater value addition through our combined capabilities. We are very excited about this transformation,” said Bas Heijnen, Managing Director, Double Effec t on this occasion.

“Considering the roll out of the recent business transformation strategy by Synechron, this is the right time for brand integration of Team Trade with Synechron as providing technology and consulting services under the merged identity will have a positive impact in the eyes of clients and other stakeholders,” said Pascal Rellier, Managing Director, Team Trade .

“For Synechron, Double Effect and Team Trade, this mutually beneficial move is a major opportunity for offering a niche, augmented set of technology as well as consulting services for the financial services industry. This brand integration will add more depth to Synechron’s current value proposition and enable our global clients to avail business solutions with a 360-degree perspective, encompassing business consulting and technology combined with digital transformation services under a single roof,” commented Faisal Husain, Co-founder and Chief Executive Officer, Synechron .

This brand integration will come into effect on April 4, 2016 and will be a critical step for Synechron in order to strategically re-align its technology and consulting service capabilities in all its service lines.

About Synechron

Synechron, one of the fastest-growing digital, business consulting & technology services providers, is a $350 million firm based in New York. Since inception in 2001, Synechron has been on a steep growth trajectory. With 5,000+ professionals operating in 16 countries across the world, it has presence across USA, Canada, UK, France, The Netherlands, Switzerland, Luxembourg, Serbia, Germany, Italy, UAE, Singapore, Hong Kong, Japan, Australia and Development Centers in India. Visit us at www.synechron.com .

Contact:

Synechron
Atul Tajave
Manager - Global Marketing & Communication
synechron-mediarelations@synechron.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye